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A B S T R A C T
Purpose
We evaluated whether motesanib (a selective oral inhibitor of vascular endothelial growth factor
receptors 1, 2, and 3; platelet-derived growth factor receptor; and Kit) combined with carboplatin/
paclitaxel improved overall survival (OS) versus chemotherapy alone in patients with nonsqua-
mous non–small-cell lung cancer (NSCLC) and in the subset of patients with adenocarcinoma.
Patients and Methods
Patients with stage IIIB/IV or recurrent nonsquamous NSCLC (no prior systemic therapy for
advanced disease) were randomly assigned 1:1 to carboplatin (area under the curve, 6 mg/ml · min) and
paclitaxel (200 mg/m2) intravenously for up to six 3-week cycles plus either motesanib 125 mg (arm A) or
placebo (arm B) once daily orally. OS was the primary end point. Secondary end points included
progression-free survival (PFS), objective response rate (ORR), adverse events (AEs), and association
between placental growth factor (PLGF) change and OS.
Results
A total of 1,090 patients with nonsquamous NSCLC were randomly assigned (arms A/B, n  541
of 549); of those, 890 had adenocarcinoma (n 448 of 442). Median OS in arms A and B was 13.0
and 11.0 months, respectively (hazard ratio [HR], 0.90; 95% CI, 0.78 to 1.04; P  .14); median OS
for the adenocarcinoma subset was 13.5 and 11.0 months, respectively (HR, 0.88; 95% CI, 0.75
to 1.03; P  .11). In descriptive analyses (arms A v B), median PFS was 5.6 months versus 5.4
months (P   .001); ORR was 40% versus 26% (P  .001). There was no association between
PLGF change and OS in arm A. The incidence of grade  3 AEs (arms A and B, 73% and 59%,
respectively) and grade 5 AEs (14% and 9%, respectively) was higher with motesanib treatment.
Conclusion
Motesanib plus carboplatin/paclitaxel did not significantly improve OS over carboplatin/paclitaxel
alone in patients with advanced nonsquamous NSCLC or in the adenocarcinoma subset.
J Clin Oncol 30:2829-2836. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Two pivotal phase III trials have laid the foundation
for using targeted antiangiogenic agents in the treat-
ment of metastatic nonsquamous non–small-cell
lung cancer (NSCLC). In the E4599 study, treatment
with bevacizumab, an anti–vascular endothelial
growth factor (VEGF) monoclonal antibody, com-
bined with carboplatin/paclitaxel significantly im-
proved objective response rate (ORR), progression-
free survival (PFS), and overall survival (OS)
compared with carboplatin/paclitaxel alone.1 In the
AVAiL (AVAstin in Lung) study, bevacizumab plus
cisplatin/gemcitabine improved PFS and ORR,
compared with placebo, but not OS.2,3
Efforts to identify drugs that inhibit key signal-
ing pathways involved in the pathogenesis of cancer
have led to the development of multitargeted agents.
Small-molecule tyrosine kinase inhibitors that block
several kinases simultaneously may offer advantages
over single-target agents.4 Furthermore, there is in-
terest in identifying patients most likely to respond
to targeted therapies based on specific biomarkers5
and/or tumor histology.6
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Motesanib is a selective oral inhibitor of VEGF receptors
(VEGFR) 1, 2, and 3; platelet-derived growth factor receptor; and Kit7
that has demonstrated antitumor activity when administered as
monotherapy8-10 or combined with chemotherapy.11 In a phase II
randomized, open-label study in advanced nonsquamous NSCLC,
ORR, PFS, and OS were estimated to be comparable among patients
who received carboplatin/paclitaxel and either motesanib 125 mg
once daily (n  61) or bevacizumab 15 mg/kg once every 3 weeks
(n  63).11 A biomarker analysis of that study showed significant
associations between increase in placental growth factor (PLGF) dur-
ing the first 3 weeks of treatment and efficacy outcomes in the mote-
sanib 125-mg once daily arm.12 PLGF is a VEGF homolog that can
promote angiogenesis by activating VEGFR-1.13
The primary objective of the MONET1 (Motesanib NSCLC
Efficacy and Tolerability) study was to determine whether motesanib
combined with carboplatin/paclitaxel improved OS, compared with
placebo plus carboplatin/paclitaxel, in patients with advanced
nonsquamous NSCLC and in the subset of patients with adenocarci-
noma histology. We also assessed whether increases in PLGF during
motesanib treatment were associated with OS.
PATIENTS AND METHODS
Eligibility
Initially, the study enrolled patients with NSCLC of all histologies. After
a planned review of data from 600 patients (including 223 with squamous
histology) in November 2008, the independent data monitoring committee
recommended that enrollment of all patients be halted and treatment of those
with squamous histology be discontinued because of higher early mortality
and a higher incidence of gross hemoptysis compared with placebo. Patients
with nonsquamous histology continued to receive treatment. The study pro-
tocol was amended in April 2009 to only allow enrollment of patients with
nonsquamous histology; enrollment resumed in June 2009. This article re-
ports results from the amended study.
Eligible patients ( 18 years of age) had histologically confirmed unre-
sectable stage IIIB with pericardial/pleural effusion or stage IV/recurrent
nonsquamous NSCLC; measurable or nonmeasurable disease per Response
Evaluation Criteria in Solid Tumors (RECIST 1.0)14; Eastern Cooperative
Oncology Group performance status  1; life expectancy  3 months; and
adequate renal, cardiac, hepatic, and hematologic function. Key exclusion
criteria were history of pulmonary hemorrhage or gross hemoptysis within
6 months of randomization; prior chemotherapy, including adjuvant chemo-
therapy within 52 weeks of randomization; symptomatic or untreated CNS
metastases; adenosquamous histology or unclear histologic type (10% squa-
mous cells); prior targeted therapy; uncontrolled hypertension; arterial or
venous thrombosis within 12 months, or bleeding diathesis or bleeding within
14 days of randomization. Study procedures were approved by an indepen-
dent ethics committee/institutional review board at each study site. All patients
provided written informed consent.
Study Design and Treatments
The study was conducted at 198 centers in 32 countries. Patients
received paclitaxel (200 mg/m2) and carboplatin (area under the curve,
6 mg/ml · min) on day 1 of each 3-week cycle for up to six cycles and were
randomly assigned 1:1 using a computerized interactive voice response
system to also receive oral motesanib 125 mg once daily (arm A) or placebo
(arm B). Randomization was stratified by disease stage (IIIB v IV/recur-
rent), weight loss in the previous 6 months before randomization ( 5%
v 5%), sex (male v female), and prior adjuvant chemotherapy (yes v no).
Treatment continued until disease progression, unacceptable toxicity, or
withdrawal of consent.
In case of treatment-related grade 3 or 4 toxicity, motesanib/placebo was
withheld until the toxicity resolved to grade 1 or baseline. Treatment could
then be resumed with a 25-mg dose reduction but was permanently discon-
tinued if more than two dose reductions were required or if grade 3 or 4
toxicity recurred after a dose delay and/or reduction or persisted for more than
3 weeks.
The primary end point was OS. Secondary end points included PFS
(from randomization to disease progression per RECIST), ORR per RECIST
1.0, and incidence of adverse events (AEs). Before unblinding, the statistical
analysis plan was amended to also assess association between motesanib
treatment-induced PLGF change and OS as a secondary end point.
Assessments
Computed tomography/magnetic resonance imaging was performed
every 61 weeks for assessment of tumor response by investigators. Objective
responses were confirmed 4 weeks after the initial response assessment. If
symptoms suggestive of disease progression occurred, patients were evaluated
for tumor response.
All AEs (from the start of treatment to 30 days after the last dose) were
recorded and graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0.
Biomarker Analysis
Serum samples were obtained before treatment on day 1 of cycles 1, 2,
and 3 and every 6 weeks thereafter. Serum PLGF was quantified using a
two-step chemiluminescent microparticle immunoassay (ARCHITECT;
Abbott Laboratories, Abbott Park, IL). Briefly, serum sample and anti-PLGF
antibody paramagnetic microparticles were incubated together; following a
wash step, anti-PLGF acridinium-labeled antibody was added. After another
incubation and wash, pretrigger and trigger solutions were added, and chemi-
luminescent signal was measured. The lower limit of quantitation was 3.4
pg/mL; the linear response range was 4 to 1,500 pg/mL.
Statistical Analysis
The study was designed to accrue approximately 1,060 patients with
nonsquamous histology to have 80% power to detect a hazard ratio (HR) of
0.80 (12.5 months v 10 months) for OS with two-sided .03 in the patients
with nonsquamous histology. The study had 80% power to detect an HR of
0.77 (13 months v 10 months) for OS with two-sided .02 in the adenocar-
cinoma subset. An split testing strategy was used to control the overall type I
error rate of the study. The primary analysis was planned at 742 and 593 deaths
among patients with nonsquamous histology and the adenocarcinoma subset,
respectively, whichever occurred later. An interim analysis was planned at 370
events among nonsquamous patients; early stopping guidelines are described
in the study protocol (Data Supplement).
OS and PFS were compared between arms A and B using stratified
log-rank tests based on the stratification factors at randomization. HRs for the
effect of motesanib on OS and PFS between arms A and B were estimated using
a stratified Cox proportional hazards model.15 Difference in ORR between
arms A and B was calculated with a stratified Cochran-Mantel-Haenszel test15
using the randomization stratification factors. The association between mote-
sanib treatment-induced PLGF change and OS was evaluated using a Cox
model with the log-transformed fold-change in PLGF from baseline at week 4
as a continuous variable. If OS and PLGF were significantly associated, fold-
change in PLGF was to be assessed based on a prespecified cutoff ( 2.0-fold
v 2.0-fold change). A hierarchical testing scheme for the secondary efficacy
end points (PFS, PLGF, and ORR) was specified if the primary end point (OS)
was met.
Efficacy analyses for OS and PFS included all randomly assigned patients
with nonsquamous histology following the intent-to-treat principle. Safety
analyses included all randomly assigned patients who received one or more
doses of motesanib/placebo. Biomarker analyses included all patients ran-
domly assigned who had PLGF values at weeks 1 (baseline) and 4 and had
received motesanib/placebo the day before the week 4 PLGF sample collection.
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RESULTS
Patients
Between July 5, 2007, and March 18, 2010, 1,090 patients with
nonsquamous NSCLC were randomly assigned to motesanib (n 541;
armA)orplacebo(n549;armB).Before theprotocolamendment, the
study also enrolled 360 patients with squamous histology. Data from this
cohort will be reported in a separate publication. Eighteen patients with
nonsquamous NSCLC did not receive motesanib (n 10) or placebo
(n8;Fig1).Mostpatientshadadenocarcinomahistology(armA,83%;
arm B, 81%), weight loss less than 5% in the previous 6 months, and stage
IV/recurrent disease (Table 1). Clinical characteristics were generally bal-
anced across treatment arms.
Treatment
Median daily doses of motesanib or placebo were 125 mg in both
treatment arms. Patients received motesanib for a median of 4.1
months (range, 0.03 to 35.9 months) and placebo for 4.1 months
(range, 0.03 to 31.5 months). Carboplatin was administered for a
median of 4.5 cycles (range, one to six cycles) in arm A and 5.0 cycles
(range, one to six cycles) in arm B; paclitaxel was administered for a
median of 4.0 cycles (range, one to six cycles) in arm A and 5.0 cycles
(range, one to six cycles) in arm B. At the time of this analysis, 519
patients (96%) in arm A and 534 patients (97%) in arm B had discon-
tinued motesanib/placebo; more patients in arm A than arm B had
discontinued for reasons other than disease progression (Fig 1). Me-
dian follow-up times were 11 months (range, 0.2 to 41 months) in arm
A and 10 months (range, 0.2 to 38 months) in arm B.
OS
Treatment with motesanib did not significantly improve OS. At
the time of this analysis, 66% of patients in arm A and 72% in arm B
had died. Among all patients with nonsquamous histology, median
OS times were 13.0 months (95% CI, 11.2 to 14.0 months) in arm A
versus 11.0 months (95% CI, 10.1 to 12.4 months) in arm B (HR, 0.90;
95% CI, 0.78 to 1.04; P .14; Fig 2A). In the adenocarcinoma subset,
median OS time was 13.5 months (95% CI, 11.3 to 14.7 months) in
arm A versus 11.0 months (95% CI, 9.9 to 12.4 months) in arm B (HR,
0.88; 95% CI, 0.75 to 1.03; P  .11; Fig 2B). Prespecified subgroup
analyses suggested longer survival among patients receiving mote-
sanib who were nonwhite (HR, 0.76; 95% CI, 0.59 to 0.97; n375) or
who were enrolled outside the United States/Canada/Australia/Euro-
pean Union (HR, 0.77; 95% CI, 0.61 to 0.98; n 414; Fig 3).
PFS
Among all patients with nonsquamous histology, median PFS times
were 5.6 months in arm A versus 5.4 months in arm B (HR, 0.79; 95% CI,
0.68 to 0.90; P .001; Fig 4A). PFS times in the adenocarcinoma
Nonsquamous and squamous patients screened
(N = 1,874)
Nonsquamous patients randomly assigned
(n = 1,090)
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Fig 1. Disposition of patients. (*) Two patients assigned to placebo treatment received at least one dose of motesanib. C/P, carboplatin/paclitaxel; QD, once daily.
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subset were similar: 5.6 months in arm A versus 5.4 months in arm B
(HR, 0.78; 95% CI, 0.67 to 0.91; P .0016; Fig 4B). P values for PFS
and other secondary efficacy end points are exploratory because the
study end point (OS) was not achieved.
Tumor Response
Most patients had measurable disease at baseline (Table 2). In
exploratory analyses, ORR for all patients with nonsquamous histol-
ogy (arm A, 40% v arm B, 26%) and for the adenocarcinoma subset
(arm A, 39% v arm B, 25%) favored arm A. Likewise, in both the
overall nonsquamous population (arm A, 80% v arm B, 74%) and the
adenocarcinoma subset (arm A, 81% v arm B, 74%), more patients
receiving motesanib than placebo had a decrease in the sum of longest
diameter at any time after baseline. Duration of response was 5.8
months (95% CI, 5.3 to 6.5 months) in arm A and 5.0 months (95%
CI, 4.4 to 5.6 months) in arm B.
Toxicity
Toxicity data are reported for all randomly assigned patients with
nonsquamous histology. The incidence of grade 3 AEs was similar
with both treatments; however, grade 4 and grade 5 AEs as well as
serious grade 3 AEs occurred more frequently in arm A (Table 3).
No specific events accounted for the imbalance in the incidence of
grade 4 or 5 AEs with the exception of grade 4 neutropenia (12% of
patients in arm A v 6% in arm B). Considering all AEs, there were a
number of events that occurred at an increased incidence of 5% in
arm A compared with placebo (Table 3). Particularly noteworthy were
diarrhea, nausea, vomiting, and abdominal pain as well as hyperten-
sion, pneumonia, and gallbladder-related disorders (eg, cholecystitis,
cholelithiasis, and gallbladder enlargement), some of which were also
reported as serious grade 3 AEs.
The incidence of AEs typically associated with VEGF pathway
inhibitors was higher in arm A with respect to hypertension (Table 3)
and grade 3 arterial thromboembolic (2% v 1% in arm B) and
hemorrhagic events (3% v 1%). Specific hemorrhagic events were
gastrointestinal hemorrhage (n 1 v n 0), pulmonary hemorrhage
(n 2 v n 1), and hemoptysis (n 3 v n 1). Grade 3 venous
thromboembolic events occurred in 4% of patients in each treat-
ment arm.
The number of patients with AEs leading to motesanib/placebo
discontinuation was higher in arm A (31%) than in arm B (15%).
Fourteen percent of patients in arm A and 9% in arm B had fatal AEs
while on study (ie, within 30 days of the last study treatment). Grade 5
AEs reported in four or more patients in either treatment arm were
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Fig 2. Overall survival (OS) time among patients who received motesanib 125 mg once daily plus carboplatin/paclitaxel (C/P) or placebo plus C/P in (A) all randomly
assigned patients with nonsquamous histology and (B) the adenocarcinoma subset.
Table 1. Baseline Demographics and Disease Characteristics
Characteristic
Arm A,
Motesanib 
C/P (n  541)
Arm B,
Placebo 
C/P (n  549)
No. % No. %
Age, years
Median 60 60
Range 23-87 21-84
Men‡ 334 62 336 61
ECOG performance status
0 188 35 207 38
 1 353 65 342 62
Past or present smoker 387 72 397 72
Race
White 362 67 353 64
Asian§ 139 26 148 27
Hispanic 28 5 38 7
Black 9 2 7 1
Other 3  1 3  1
Histology
Adenocarcinoma 448 83 442 81
Bronchoalveolar carcinoma 14 3 15 3
Large-cell carcinoma 26 5 35 6
Undifferentiated 21 4 21 4
Other 32 6 36 7
Disease stage at study entry‡
IIIB with pericardial/pleural effusion 73 13 79 14
IV/recurrent 468 87 470 86
Weight loss  5% in previous 6
months† 397 73 407 74
Prior adjuvant chemotherapy‡ 11 2 12 2
Abbreviations: C/P, carboplatin/paclitaxel; ECOG, Eastern Cooperative Oncol-
ogy Group.
All randomly assigned patients with nonsquamous histology.
‡Randomization stratification factors.
§Includes Japanese patients.
Scagliotti et al
2832 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
2016 from 130.192.124.11
Information downloaded from jco.ascopubs.org and provided by at Bibl.Centralizzata medicina e chirurgia on January 4,
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
pneumonia (n 7 v n 0), general physical health deterioration
(n  6 v n  1), respiratory failure (n  5 v n  2), pulmonary
embolism (n 3 v n 6), and cardiorespiratory arrest (n1 v n4).
Assessment of PLGF As a Biomarker
MONET1 confirmed the pharmacodynamic increase in PLGF in
response to motesanib treatment that was reported previously9,12,16,17
(data not shown). However, among patients in the motesanib arm
who had evaluable PLGF samples at baseline (n 356, 33%), there
was no association between the log-transformed fold-change in PLGF
from baseline to week 4 (continuous variable) and OS (unadjusted
Cox model, HR, 0.98; 95% CI, 0.79 to 1.22; P .868). There was no
association between the prespecified 2.0-fold change in PLGF from
baseline at week 4 and OS (HR, 0.88; 95% CI, 0.67 to 1.15, P .340).
Similarly, there was no association between a  2.0-fold change in
PLGF and PFS or ORR.
DISCUSSION
In this large phase III study, motesanib plus carboplatin/paclitaxel did
not significantly improve OS compared with placebo plus carbopla-
tin/paclitaxel in the overall nonsquamous patient population or the
subset of patients with adenocarcinoma. Although the study did not
meet its primary end point, improvements in PFS and ORR in arm A
suggest some antitumor activity of the combination in this setting.
However, the study also showed that motesanib treatment was asso-
ciated with increased toxicity, which may have affected efficacy. Spe-
cifically, the incidence of grade 4 and 5 AEs, serious grade3 AEs, and
AEs leading to discontinuation was higher with motesanib treatment.
Gastrointestinal events, hypertension, pneumonia, cholecystitis, and
other gallbladder-related disorders generally occurred more fre-
quently in the motesanib arm, which is consistent with previous mote-
sanib studies in advanced nonsquamous NSCLC.11,18 Cholecystitis in
particular is a motesanib-specific AE that had emerged in earlier
monotherapy and chemotherapy combination studies.8,9,11,18-20 Most
of these AEs are likely the result of motesanib’s actions on angio-
genic signaling pathways (motesanib potently inhibits VEGFR1,
-2, and -3; Kit; and PDGFR7). Toxicity in the motesanib arm
appeared to have contributed to treatment discontinuation and
may also have resulted in noncompliance with treatment. The
study initially permitted enrollment of both nonsquamous and
squamous NSCLC; however, the protocol was later amended to
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Fig 3. Overall survival time by patient
subgroups for all randomly assigned pa-
tients with nonsquamous histology. Euro-
pean Union countries include Austria,
Bulgaria, Czech Republic, France, Ger-
many, Greece, Hungary, Ireland, Italy, Po-
land, Romania, Slovakia, Spain, and United
Kingdom. ECOG, Eastern Cooperative On-
cology Group.
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exclude patients with squamous histology because of an increased risk
of death and hemoptysis. This finding was consistent with the greater
risk of hemoptysis reported for patients with squamous NSCLC who
received bevacizumab,21 but not with results from the Evaluation of
Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC (ESCAPE)
study, which showed no increased risk of fatal bleeding events with
sorafenib treatment among patients with squamous histology.22
A number of phase III studies have assessed VEGF pathway
inhibitors as first-line therapy for advanced NSCLC. At present, only
one has demonstrated an OS benefit.1 Sorafenib plus chemotherapy
did not achieve OS improvements in either the ESCAPE22 (sorafenib
plus carboplatin/paclitaxel in squamous or nonsquamous NSCLC)
or NEXUS23 (NSCLC Research Experience Utilizing Sorafenib;
sorafenib plus cisplatin/gemcitabine in nonsquamous NSCLC) stud-
ies, although PFS was improved in NEXUS. Lastly, in BR24, a phase
II/III study of carboplatin/paclitaxel with or without cediranib in
squamous or nonsquamous NSCLC, PFS and ORR were improved
over placebo plus carboplatin/paclitaxel; however, the study was
halted because cediranib at 30 mg/d was associated with increased
incidences of severe hypertension, gastrointestinal toxicity, and
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Fig 4. Progression-free survival time among patients who received motesanib 125 mg once daily plus carboplatin/paclitaxel (C/P) or placebo plus C/P in (A) all randomly
assigned patients with nonsquamous histology and (B) the adenocarcinoma subset.
Table 2. Tumor Response per RECIST
Response
Nonsquamous Analysis Set Adenocarcinoma Subanalysis Set
Arm A,
Motesanib  C/P
(n  541)
Arm B,
Placebo  C/P
(n  549)
Arm A,
Motesanib  C/P
(n  448)
Arm B,
Placebo  C/P
(n  442)
No. % No. % No. % No. %
Patients with measurable disease at baseline 523 97 527 96 433 97 422 95
Response assessment
Confirmed CR 5  1 2  1 5 1 1  1
Confirmed PR 204 39 133 25 166 38 105 25
SD† 207 40 265 50 182 42 214 51
PD 35 7 80 15 26 6 64 15
Unevaluable‡ 5  1 2  1 5 1 2  1
Not done§ 67 13 45 9 49 11 36 9
Confirmed objective response (CR or PR) 209 40 135 26 171 39 106 25
Difference, % 14.3 14.4
95% CI 8.7 to 20.0 8.2 to 20.6
P  .001  .001
Responders with measurable disease at baseline 209 39 135 25 171 38 106 24
Duration of response, months 5.8 5.0 5.9 5.5
95% CI 5.3 to 6.5 4.4 to 5.6 5.5 to 6.9 4.4 to 5.7
Abbreviations: C/P, carboplatin/paclitaxel; CR, complete response; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid
Tumors; SD, stable disease.
Assessed by investigators per RECIST version 1.0. The nonsquamous analysis set included all patients randomly assigned who had nonsquamous histology. The
adenocarcinoma analysis set included all patients randomly assigned who had adenocarcinoma histology. The denominator for all response categories was the
number of patients with measurable disease at baseline.
†Patients with an assessment of PR or CR not confirmed at least 4 weeks later were classified as having SD.
‡Patients with an assessment of CR, PR, or SD before the first scheduled assessment of response without an additional assessment of response.
§Patients for whom imaging was not performed at the scheduled assessment of response.
From Cochran-Mantel-Haenszel test stratified by the randomization stratification factors.
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febrile neutropenia and was not considered tolerable.24 Further-
more, two randomized studies evaluating VEGF pathway
inhibitors as second-line therapy in advanced NSCLC failed to meet
their primary end points.25,26 The results from MONET1 add to the
growing body of evidence suggesting that VEGF pathway inhibitors in
combination with chemotherapy do not provide a significant clinical
benefit to unselected patients with (nonsquamous) NSCLC. Addi-
tional studies do not seem to be warranted unless better patient selec-
tion using biomarkers, for example, can be achieved. Despite ongoing
efforts,27 such biomarkers have remained elusive. MONET1 is the first
large phase III study to prospectively test a biomarker hypothesis for
an antiangiogenic therapy in NSCLC. Data from the preceding phase
II study of carboplatin/paclitaxel plus motesanib or bevacizumab sug-
gested that increased PLGF might be a marker of therapeutic response
to motesanib treatment.12 This hypothesis was supported by similar
findings of associations between fold-change in PLGF and outcomes
in patients with advanced thyroid cancer17 and human epidermal
growth factor receptor 2–negative metastatic breast cancer12 receiving
motesanib. However, the data could not be confirmed in MONET1;
there was no association between changes in PLGF and OS in the
motesanib arm.
Previous studies suggested that NSCLC tumor histology influ-
ences response to certain chemotherapy regimens28 and targeted
agents (including VEGF pathway inhibitors).6,29 A retrospective anal-
ysis of the E4599 study reported a 4-month improvement in OS with
the addition of bevacizumab to carboplatin/paclitaxel among patients
with adenocarcinoma histology.6 On the basis of those data, we con-
ducted a prospectively defined analysis of efficacy in the subset of
patients with adenocarcinoma histology. Although a statistically sig-
nificant improvement in OS was not achieved, it is noteworthy that in
prespecified subgroup analyses, the HR for patients with adenocarci-
noma histology was 0.880 versus 1.012 for those with other nonsqua-
mous histologies.
Prespecified subgroup analyses also indicated differences in OS
by ethnicity and geographic location. The subanalyses data suggest
that a highly selected patient population might have a greater likeli-
hood to benefit. Specifically, results from the ethnicity/regional
subanalysis indicate that Asian patients (one fourth of the enrolled
patient population) may achieve better clinical outcome than non-
Asian patients (data not shown), which may warrant a separate
study in the future.
In summary, treatment with motesanib plus carboplatin/pacli-
taxel in this phase III study did not significantly improve OS and was
associated with a higher incidence of AEs compared with placebo plus
carboplatin/paclitaxel in patients with advanced nonsquamous
NSCLC and in the subset of patients with adenocarcinoma histology.
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Table 3. Adverse Events
AE
Arm A,
Motesanib
 C/P
(n  533)
Arm B,
Placebo
 C/P
(n  539)
No. % No. %
Patients with any AE 512 96 520 96
Grade 3 201 38 192 36
Grade 4 113 21 77 14
Grade 5 74 14 50 9
AEs with a  5% difference in
incidence between arms
Diarrhea 255 48 118 22
Nausea 222 42 176 33
Decreased appetite 186 35 147 27
Vomiting 178 33 142 26
Fatigue 177 33 151 28
Neutropenia 149 28 110 20
Hypertension 139 26 35 6
Thrombocytopenia 112 21 83 15
Rash 97 18 57 11
Weight decreased 93 17 46 9
Abdominal pain 90 17 30 6
Headache 82 15 49 9
Stomatitis 59 11 26 5
Proteinuria 47 9 16 3
Gallbladder-related disorder 44 8 2  1
Patients with serious AEs 261 49 184 34
Serious grade  3 AEs†
Neutropenia 28 5 12 2
Diarrhea 25 5 4  1
Febrile neutropenia 23 4 15 3
Pneumonia 20 4 7 1
Dehydration 19 4 4  1
Non–small-cell lung cancer‡ 16 3 12 2
Thrombocytopenia 14 3 6 1
Pulmonary embolism 12 2 17 3
Anemia 12 2 11 2
Dyspnea 11 2 20 4
Vomiting 11 2 7 1
General physical health deterioration 11 2 4  1
Cholecystitis 11 2 0 0
NOTE. AEs are reported for all patients with nonsquamous histology who
received  1 dose of motesanib or placebo and include events occurring
during treatment and within 30 days of the last administration of study
treatment.
Abbreviations: AE, adverse event; C/P, carboplatin/paclitaxel.
Includes cholecystitis, acute and chronic cholecystitis, cholelithiasis; gall-
bladder enlargement, edema, and perforation; hydrocholecystis (the differ-
ence in incidence between arms for individual AEs was  5%).
†In  2% of patients in either treatment arm.
‡Patients with non–small-cell lung cancer reported as an AE by investigators.
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